(VIANEWS) – Shares of Arcturus Therapeutics (NASDAQ: ARCT) rose by a staggering 16.46% in 5 sessions from $24.61 at 16.46, to $28.66 at 14:50 EST on Monday, after five sequential sessions in a row of gains. NASDAQ is rising 0.21% to $13,816.77, following the last session’s upward trend.
Arcturus Therapeutics’s last close was $28.68, 15.15% below its 52-week high of $33.80.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $4.21.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 6.81. Meaning, the purchaser of the share is investing $6.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.3%.
Volatility
Arcturus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was 3.93%, 0.36%, and 2.99%.
Arcturus Therapeutics’s highest amplitude of average volatility was 3.93% (last week), 2.81% (last month), and 2.99% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Arcturus Therapeutics’s stock is considered to be oversold (<=20).
Sales Growth
Arcturus Therapeutics’s sales growth is 64.2% for the current quarter and 455% for the next.
More news about Arcturus Therapeutics (ARCT).
